Literature DB >> 28669481

Impact of the opioid system on the reproductive axis.

Bettina Böttcher1, Beata Seeber1, Gerhard Leyendecker2, Ludwig Wildt3.   

Abstract

Endogenous opioids, first described more than 40 years ago, have long been recognized for their main role as important neuromodulators within the central nervous system. More recently endogenous opioids and their receptor have been identified in a variety of reproductive and nonreproductive tissues outside the central nervous system. Their role within these tissues and organs, however, is only incompletely understood. In the central nervous system, endogenous opioids inhibit pulsatile GnRH release, in part mediating the stress response within the central nervous-pituitary gonadal axis, resulting in hypothalamic amenorrhea. In the ovary, the presence of endogenous opioids primarily produced by granulosa cells has been demonstrated within the follicular fluid, likely influencing oocyte maturation. In hypothalamic amenorrhea, normal cycles can be restored by the administration of opioid antagonists, such as naltrexone. In polycystic ovarian syndrome, endogenous opioids have found to be elevated and may stimulate insulin secretion from the endocrine pancreas. This effect can be inhibited by opioid antagonists, resulting in a decrease of circulating insulin levels in response to glucose challenge. Endogenous opioids may also play a role in the pathogenesis of ovarian hyperstimulation syndrome. In summary, endogenous opioids exert a wide variety of actions within the reproductive system and are worthy of further scientific study.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  endogenous opioids; hypothalamic amenorrhea; naltrexone; polycystic ovary syndrome; reproductive hormone axis; β-Endorphin

Mesh:

Substances:

Year:  2017        PMID: 28669481     DOI: 10.1016/j.fertnstert.2017.06.009

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  7 in total

1.  Phosphoproteomic and Functional Analyses Reveal Sperm-specific Protein Changes Downstream of Kappa Opioid Receptor in Human Spermatozoa.

Authors:  Itziar Urizar-Arenaza; Nerea Osinalde; Vyacheslav Akimov; Michele Puglia; Luz Candenas; Francisco Maria Pinto; Iraia Muñoa-Hoyos; Marta Gianzo; Roberto Matorras; Jon Irazusta; Blagoy Blagoev; Nerea Subiran; Irina Kratchmarova
Journal:  Mol Cell Proteomics       Date:  2019-01-08       Impact factor: 5.911

Review 2.  Functional hypothalamic and drug-induced amenorrhea: an overview.

Authors:  A Lania; L Gianotti; I Gagliardi; M Bondanelli; W Vena; M R Ambrosio
Journal:  J Endocrinol Invest       Date:  2019-02-11       Impact factor: 4.256

Review 3.  Modeling prenatal opioid exposure in animals: Current findings and future directions.

Authors:  Elizabeth M Byrnes; Fair M Vassoler
Journal:  Front Neuroendocrinol       Date:  2017-09-28       Impact factor: 8.606

4.  Is opioid use safe in women trying to conceive?

Authors:  Kerry S Flannagan; Sunni L Mumford; Lindsey A Sjaarda; Jeannie G Radoc; Neil J Perkins; Victoria C Andriessen; Jessica R Zolton; Robert M Silver; Enrique F Schisterman
Journal:  Epidemiology       Date:  2020-11       Impact factor: 4.860

5.  Beta endorphin in serum and follicular fluid of PCOS- and non-PCOS women.

Authors:  Nikolai Jaschke; Fabian Lunger; Ludwig Wildt; Beata Seeber
Journal:  Arch Gynecol Obstet       Date:  2018-05-28       Impact factor: 2.344

Review 6.  Endometriosis and polycystic ovary syndrome are diametric disorders.

Authors:  Natalie L Dinsdale; Bernard J Crespi
Journal:  Evol Appl       Date:  2021-05-14       Impact factor: 4.929

7.  Infertility management in primary care.

Authors:  Angela Thable; Elsie Duff; Cheryl Dika
Journal:  Nurse Pract       Date:  2020-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.